133 related articles for article (PubMed ID: 36502651)
1. Standard deviations of MR signal intensities show a consistent trend during imaging follow-ups for glioblastoma patients when corrected for non-biological heterogeneity due to hardware and software variation.
Sarkar S; Rojas R; Lespinasse E; Zhang XF; Zeron R
Clin Neurol Neurosurg; 2023 Jan; 224():107553. PubMed ID: 36502651
[TBL] [Abstract][Full Text] [Related]
2. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Dhermain F
Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma.
Yang D; Rao G; Martinez J; Veeraraghavan A; Rao A
Med Phys; 2015 Nov; 42(11):6725-35. PubMed ID: 26520762
[TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced MR Imaging versus Contrast-enhanced US: A Comparison in Glioblastoma Surgery by Using Intraoperative Fusion Imaging.
Prada F; Vitale V; Del Bene M; Boffano C; Sconfienza LM; Pinzi V; Mauri G; Solbiati L; Sakas G; Kolev V; D'Incerti L; DiMeco F
Radiology; 2017 Oct; 285(1):242-249. PubMed ID: 28562204
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Cha S; Lupo JM; Chen MH; Lamborn KR; McDermott MW; Berger MS; Nelson SJ; Dillon WP
AJNR Am J Neuroradiol; 2007; 28(6):1078-84. PubMed ID: 17569962
[TBL] [Abstract][Full Text] [Related]
7. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
[TBL] [Abstract][Full Text] [Related]
8. The effect of glioblastoma heterogeneity on survival stratification: a multimodal MR imaging texture analysis.
Liu Y; Zhang X; Feng N; Yin L; He Y; Xu X; Lu H
Acta Radiol; 2018 Oct; 59(10):1239-1246. PubMed ID: 29430935
[TBL] [Abstract][Full Text] [Related]
9. Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy.
Duma CM; Kim BS; Chen PV; Plunkett ME; Mackintosh R; Mathews MS; Casserly RM; Mendez GA; Furman DJ; Smith G; Oh N; Caraway CA; Sanathara AR; Dillman RO; Riley AS; Weiland D; Stemler L; Cannell R; Abrams DA; Smith A; Owen CM; Eisenberg B; Brant-Zawadzki M
J Neurosurg; 2016 Dec; 125(Suppl 1):40-49. PubMed ID: 27903197
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme.
Chen X; Fang M; Dong D; Liu L; Xu X; Wei X; Jiang X; Qin L; Liu Z
Acad Radiol; 2019 Oct; 26(10):1292-1300. PubMed ID: 30660472
[TBL] [Abstract][Full Text] [Related]
11. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
12. Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
Chung WJ; Kim HS; Kim N; Choi CG; Kim SJ
Radiology; 2013 Nov; 269(2):561-8. PubMed ID: 23878286
[TBL] [Abstract][Full Text] [Related]
13. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
Naeini KM; Pope WB; Cloughesy TF; Harris RJ; Lai A; Eskin A; Chowdhury R; Phillips HS; Nghiemphu PL; Behbahanian Y; Ellingson BM
Neuro Oncol; 2013 May; 15(5):626-34. PubMed ID: 23444259
[TBL] [Abstract][Full Text] [Related]
14. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.
Barajas RF; Phillips JJ; Parvataneni R; Molinaro A; Essock-Burns E; Bourne G; Parsa AT; Aghi MK; McDermott MW; Berger MS; Cha S; Chang SM; Nelson SJ
Neuro Oncol; 2012 Jul; 14(7):942-54. PubMed ID: 22711606
[TBL] [Abstract][Full Text] [Related]
15. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme.
Stringfield O; Arrington JA; Johnston SK; Rognin NG; Peeri NC; Balagurunathan Y; Jackson PR; Clark-Swanson KR; Swanson KR; Egan KM; Gatenby RA; Raghunand N
Tomography; 2019 Mar; 5(1):135-144. PubMed ID: 30854451
[TBL] [Abstract][Full Text] [Related]
16. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric magnetic resonance imaging to differentiate high-grade gliomas and brain metastases.
Mouthuy N; Cosnard G; Abarca-Quinones J; Michoux N
J Neuroradiol; 2012 Dec; 39(5):301-7. PubMed ID: 22197404
[TBL] [Abstract][Full Text] [Related]
18. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
Szeto MD; Chakraborty G; Hadley J; Rockne R; Muzi M; Alvord EC; Krohn KA; Spence AM; Swanson KR
Cancer Res; 2009 May; 69(10):4502-9. PubMed ID: 19366800
[TBL] [Abstract][Full Text] [Related]
19. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
[TBL] [Abstract][Full Text] [Related]
20. Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM.
Essock-Burns E; Phillips JJ; Molinaro AM; Lupo JM; Cha S; Chang SM; Nelson SJ
J Magn Reson Imaging; 2013 Aug; 38(2):388-400. PubMed ID: 23281184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
